Transdermal CBD Gel for Focal Epilepsy Seizure Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for epilepsy, particularly drug-resistant focal epilepsy, fail to adequately reduce seizure frequency and are associated with significant adverse effects when orally administered cannabidiol (CBD).
Innovation Solution
Transdermal delivery of CBD as a gel formulation, providing controlled, twice-daily dosing to bypass first-pass metabolism and gastrointestinal tract, thereby reducing adverse events and enhancing bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oral administration of CBD is used to treat epilepsy, then seizure frequency may be reduced, but adverse effects and poor bioavailability occur due to first-pass metabolism
Solution Approach 1:
The patent introduces a transdermal gel formulation as an intermediary delivery system that mediates between the CBD substance and the body's absorption systems. This gel-based transdermal delivery system bypasses the gastrointestinal tract and first-pass metabolism, directly delivering CBD through the skin into the bloodstream, thereby reducing adverse effects while maintaining seizure frequency reduction efficacy
Solution Approach 2:
The patent replaces the oral mechanical digestion and absorption system with a transdermal delivery mechanism. Instead of relying on gastrointestinal absorption and hepatic metabolism, the system uses cutaneous absorption through the skin, substituting the metabolic processing step that causes first-pass metabolism and adverse effects
2Reliability
If oral administration of CBD is used to treat epilepsy, then seizure frequency may be reduced, but bioavailability is poor due to first-pass metabolism
Solution Approach 1:
The transdermal gel formulation acts as an intermediary that circumvents the first-pass metabolism barrier. By delivering CBD through the skin into the systemic circulation, the formulation ensures higher bioavailability of the active substance, allowing more CBD to reach the brain and other target tissues without being metabolized by the liver first
Solution Approach 2:
The patent substitutes the oral absorption pathway with a transdermal absorption pathway. This replacement eliminates the first-pass metabolism step that reduces bioavailability, directly delivering CBD into the systemic circulation where it can reach target tissues more effectively
3Object-affected harmful factors
If transdermal CBD gel is administered to reduce seizure frequency, then adverse effects are reduced, but device complexity increases
Solution Approach 1:
The patent changes the physical and chemical parameters of CBD delivery by formulating it in a gel base with specific permeation enhancers. This parameter change enables transdermal penetration while maintaining simplicity of application - the user simply applies the gel to the skin without complex mechanisms
Solution Approach 2:
The transdermal gel is designed as a simple, easily applied formulation that can be disposed of after single use. The gel application itself is a simple, transient process that delivers CBD effectively without requiring complex, reusable devices or mechanisms
4Stability of the object's composition
If transdermal CBD gel is administered twice daily, then controlled dosing is achieved, but administration frequency increases
Solution Approach 1:
The patent establishes a periodic administration schedule of twice daily applications. This periodic action provides controlled dosing by delivering CBD at consistent intervals, maintaining stable plasma levels and effective seizure frequency reduction while establishing a predictable administration rhythm
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Transdermal CBD gel effectively reduces seizure frequency by up to 65% in adults with drug-resistant focal epilepsy, with improved safety profile and reduced adverse effects compared to oral administration.
Implementation Method 1
Transdermal delivery of CBD as a gel formulation, providing controlled, twice-daily dosing to bypass first-pass metabolism and gastrointestinal tract
Data Source
AI summary
The present technology relates to a method of reducing seizure frequency in a subject having epilepsy by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein the seizure frequency is reduced.